



Robotic Versus Laparoscopic Pancreaticoduodenectomy: An Up-To-Date System Review and Meta-Analysis

Lanwei Ouyang^{1†}, Jia Zhang^{2†}, Qingbo Feng^{3†}, Zhiguang Zhang¹, Hexing Ma⁴ and Guodong Zhang^{4*}

¹ Department of Thoracic Surgery, The 3rd Affiliated Hospital Of Chengdu Medical College, Pidu District People's Hospital, Chengdu, China, ² Department of Breast Surgery, West China Hospital of Sichuan University, Chengdu, China, ³ Department of Liver Surgery and Liver Transplantation Centre, West China Hospital, Sichuan University, Chengdu, China, ⁴ Department of General Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China

OPEN ACCESS

Edited by:

Gianluca Rompianesi, University of Naples Federico II, Italy

Reviewed by:

Benedetto lelpo, Hospital del Mar, Spain Bhavin Vasavada, Consultant, Ahmedabad, India Chang Moo Kang, Yonsei University College of Medicine, South Korea

> ***Correspondence:** Guodong Zhang gdzhang1908@126.com

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Surgical Oncology, a section of the journal Frontiers in Oncology

Received: 13 December 2021 Accepted: 24 January 2022 Published: 25 February 2022

Citation:

Ouyang L, Zhang J, Feng Q, Zhang Z, Ma H and Zhang G (2022) Robotic Versus Laparoscopic Pancreaticoduodenectomy: An Up-To-Date System Review and Meta-Analysis. Front. Oncol. 12:834382. doi: 10.3389/fonc.2022.834382 **Background:** Although minimally invasive pancreaticoduodenectomy has gained worldwide interest, there are limited comparative studies between two minimally invasive pancreaticoduodenectomy techniques. This meta-analysis aimed to compare the safety and efficacy of robotic and laparoscopic pancreaticoduodenectomy (LPD), especially the difference in the perioperative and short-term oncological outcomes.

Methods: PubMed, China National Knowledge Infrastructure (CNKI), Wanfang Data, Web of Science, and EMBASE were searched based on a defined search strategy to identify eligible studies before July 2021. Data on operative times, blood loss, overall morbidity, major complications, vascular resection, blood transfusion, postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), conversion rate, reoperation, length of hospital stay (LOS), and lymph node dissection were subjected to meta-analysis.

Results: Overall, the final analysis included 9 retrospective studies comprising 3,732 patients; 1,149 (30.79%) underwent robotic pancreaticoduodenectomy (RPD), and 2,583 (69.21%) underwent LPD. The present meta-analysis revealed nonsignificant differences in operative times, overall morbidity, major complications, blood transfusion, POPF, DGE, reoperation, and LOS. Alternatively, compared with LPD, RPD was associated with less blood loss (p = 0.002), less conversion rate (p < 0.00001), less vascular resection (p = 0.0006), and more retrieved lymph nodes (p = 0.01).

Conclusion: RPD is at least equivalent to LPD with respect to the incidence of complication, incidence and severity of DGE, and reoperation and length of hospital stay. Compared with LPD, RPD seems to be associated with less blood loss, lower conversion rate, less vascular resection, and more retrieved lymph nodes.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier CRD2021274057

Keywords: minimally invasive surgery, robotic pancreaticoduodenectomy, laparoscopic pancreaticoduodenectomy, Da Vinci, meta-analysis

1

Robotic Versus Laparoscopic Pancreaticoduodenectomy

INTRODUCTION

Pancreaticoduodenectomy is a very complex procedure and is considered to be the standard of surgical treatment for both benign and malignant cancer in the periampullary region and pancreatic head (1). Gagner et al. reported the first successful laparoscopic pancreaticoduodenectomy (LPD) in 1994 (2). Almost a decade later, the development of innovative robotic platforms has later opened a new horizon for surgical treatment of pancreatic cancer, with Giulianotti et al. performing the first robotic pancreaticoduodenectomy (RPD) in Italy in 2003 (3). RPD and LPD are both minimally invasive treatments for pancreatic and periampullary malignancies and some benign diseases, but only 285 reported LPD cases have been reported as of 2011, and the safety and feasibility of RPD and LPD remain controversial (4).

To date, although several studies reporting on minimally invasive pancreaticoduodenectomy have been reported, a few studies compare one minimally invasive technique to open (5–7). Pooled data from these retrospective studies have shown that RPD was associated with less blood loss and shorter hospital stay as compared with open pancreaticoduodenectomy. At present, evidence comparing the benefits of RPD and LPD is limited. Although one meta-analysis has compared the safety and feasibility of RPD with LPD, the meta-analysis comprised only 6 studies, and most of them are of small sample size and low quality and have no randomized controlled trial (RCT), which limited them to deduce objective conclusion (8).

In the present study, we performed a meta-analysis of updated data from currently available studies to compare perioperative outcomes and short-term oncological outcomes after RPD and LPD.

METHODS

Search Strategy and Study Selection

A systematic review was performed and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the study protocol was registered at PROSPERO with the registration number CRD2021274057 (9). Given that the first RPD was reported in 2003, a systematic literature search for published studies that investigated RPD versus LPD was performed in PubMed, EMBASE, Web of Science, CNKI, and Wanfang Data, from January 1, 2003, to July 25, 2021, by two authors (LO and JZ). The combinations of the following keywords were used: RPD, LPD, Da Vinci surgery, and minimally invasive surgery. In order to gain additional studies, the references of eligible studies were manually searched.

Inclusion and Exclusion Criteria

All titles and abstracts were screened and identified eligible studies according to the following criteria by two investigators (LO and JZ) independently.

Articles meeting these criteria will be included in the analysis: 1) participants, patients' age >18. 2) Types of interventions: RPD

and LPD. 3) Types of studies: retrospective studies, cohort studies, case-control studies, and RCTs. 4) Data available on interesting perioperative and oncological outcomes. 5) Studies published in English or Chinese.

Exclusion criteria were as follows: 1) data that were incomplete and 2) editorials, abstracts, letters, case reports, and expert opinions.

Data Extraction and Quality Assessment

The original data from all candidate articles were individually assessed and extracted by two reviewers (LO and JZ) by using a unified datasheet, and any ambiguity was resolved by a third researcher (QF). The major data extraction includes the following: name of the first or corresponding author, study design, publication year, country, sample size, mean age, gender, body mass index, operative times, bleeding, overall complications, major complications, tumor size, number of retrieved lymph nodes (LNs), blood transfusion, vascular resection, blood transfusion, postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), conversion rate, and reoperation. The Newcastle–Ottawa Scale (NOS) was adopted to assess the quality of the eligible studies (10). Every included study was independently evaluated by two authors (LO and JZ), and a NOS score ≥ 6 is considered as being of high quality.

Statistical Analysis

The Review Manager 5.3 software was used for statistical analyses. 95% CI and mean difference (MD) were used for continuous data, while dichotomous data used odds ratio (OR). The method originally described by Hozo et al. was used to convert medians with ranges into means with SDs (11). Begg's funnel plot and Egger's test were used to assess potential publication bias. Statistical heterogeneity was quantified using Higgin's I² index. A fixed-effects model (FEM) was adopted when heterogeneity is low or moderate (I² < 50%), while heterogeneity is high (I² ≥ 50%) when a random-effects model (REM) was used.

RESULTS

Characteristics of the Included Studies

Finally, a total of 523 relevant English and Chinese publications from various electronic databases were yielded. Finally, according to the inclusion criteria, 9 retrospective studies (12–20) comparing RPD and LPD in a total of 3,732 patients (1,149 and 2,583 patients underwent RPD and LPD, respectively) were included for further analysis. A flow diagram of our analysis protocol is shown in **Figure 1**. The general information and summary of NOS scores of all the included studies are given in **Table 1**.

Operative Outcomes

Operative Time

Eight of the included 8 studies that encompassed 2,109 patients (984 and 1,125 underwent RPD and LPD, respectively) reported



operative time. The present meta-analysis showed that RPD has a similar operative time as compared with the LPD group (MD = 13.74 min; 95% CI –9.46 to 36.94; p = 0.25). Heterogeneity was high ($I^2 = 96\%$) and analyzed in the REM (**Figure 2A**).

Blood Loss

Five studies with a total of 363 patients had reported the bleeding volume. A meta-analysis of 5 studies indicated that RPD had less blood loss as compared to LPD (MD = -120.47 ml; 95% CI -171.09 to -69.85; p < 0.00001). Heterogeneity was high (I² = 76%) and analyzed in the REM (**Figure 2B**).

Postoperative Outcomes

Number of Retrieved Lymph Node

The number of retrieved LN data was available in 3 studies. Noticeably, the meta-analysis suggested that RPD present markedly more retrieved LN than the LPD group (OR = 3.34; 95% CI 0.81 to 5.88; p = 0.001). Heterogeneity was high ($I^2 = 89\%$) and analyzed in the REM (**Figure 3A**).

Length of Stay

Length of stay data were available in 9 studies. The meta-analysis showed no difference in hospital stay between the two groups

TABLE 1 | Characteristics of included studies

Author (year)	Type of study	Period	Country	Patients (n)		Age	(years)	Gender (M/F)		BMI		NOS
				RPD	LPD	RPD	LPD	RPD	LPD	RPD	LPD	
Liu (2016)	Retrospective	2015– 2016	China	27	25	57.16 ± 8.56	60.54 ± 18.25	14/13	12/13	NA	NA	8
Nassour (2017)	Retrospective	2014– 2015	USA	193	235	63.5 ± 11.9	63.4 ± 11.6	101/92	129/ 106	27.8 ± 5.3	27.6 ± 6.6	7
Zimmerman (2017)	Retrospective	2014– 2015	USA	211	280	66 (68–72)	64 (57–72)	109/ 102	159/ 121	27.3 (23.8– 30.9)	26.9 (23.5– 30.9)	7
Nassour (2018)	Retrospective	2010– 2013	USA	165	1458	66.5	66.3	81/84	756/ 702	NA	NA	7
Xourafas (2018)	Retrospective	2014– 2016	USA	409	418	64 (18–88)	63 (19–87)	216/ 193	233/ 185	27.5 (19–51)	27.6 (16–67)	7
Zhang (2018)	Retrospective	2013– 2017	China	20	20	68 (50–78)	64 (42–76)	12/8	11/9	24.8 ± 2.5	24.0 ± 3.5	6
Goh (2018)	Retrospective	2014– 2017	Singapore	10	20	70 (53–78)	62.5 (24–79)	5/5	16/4	21.3 (18–27.6)	20.6 (14–26)	7
Oosten (2020)	PSM	2011– 2019	USA	90	90	67 (60–73)	67 (58–75)	NA	NA	26 (23–29)	25 (22–29)	8
Xu (2021)	Retrospective	2016– 2019	China	24	37	64.0 ± 9.4	61.0 ± 9.6	11/11	20/17	20.0 (18.8– 21.9)	20.4 (19.2– 21.4)	8

RPD, robotic pancreaticoduodenectomy; LPD, laparoscopic pancreaticoduodenectomy; M/F, male/female; BMI, body mass index; NA, not available; NOS, Newcastle–Ottawa Scale; PSM, propensity score matching.

(MD = -1.29; 95% CI -2.64 to 0.05; p = 0.06), with high heterogeneity (I² = 89%) in the REM (**Figure 3B**).

Eight studies that encompassed 2,109 patients (984 and 1,125 underwent RPD and LPD, respectively) reported the overall

complications. Data analysis of 2,109 patients revealed that two

approaches had similar overall complication rates (OR = 1.03;

95% CI 0.87 to 1.23; p = 0.71) with low heterogeneity ($I^2 = 20\%$)

Overall Complications

and analyzed in FEM (Figure 4A).

Major Complications

Only two studies reported the major complications. The metaanalysis showed no difference in major complications in the two groups (OR = 1.08; 95% CI 0.74 to 1.58; p = 0.67), with no heterogeneity (I² = 0%) in the FEM (**Figure 4B**).

Postoperative Pancreatic Fistula

POPF data were available in 8 studies. The meta-analysis showed that RPD has similar POPF as compared with the LPD group (OR = 0.99; 95% CI 0.79 to 1.24; p = 0.94), with no heterogeneity ($I^2 = 0\%$) in the FEM (**Figure 5A**).





Delayed Gastric Emptying

DGE data were available in 7 studies. The meta-analysis showed that RPD has similar DGE as compared with the LPD group (OR = 0.86; 95% CI 0.68 to 1.10; p = 0.22), with no heterogeneity ($I^2 = 0\%$) in the FEM (**Figure 5B**).

and the result of the meta-analysis revealed that RPD has less vascular resection than the LPD group (OR = 0.51; 95% CI 0.34 to 0.75; p = 0.0006) (Figure 6A).

Blood Transfusion

Vascular Resection

Four studies that included 1,776 patients (823 who underwent RPD and 953 who underwent LPD) assessed vascular resection,

Four studies that included 1,405 patients (702 who underwent RPD and 703 who underwent LPD) assessed blood transfusion, and the result of meta-analysis revealed that RPD has similar blood transfusion as compared with the



	RPD)	LPD			Odds Ratio			Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year		M-H, Fixed, 95% Cl	
Liu-2016	4	27	5	25	2.9%	0.70 [0.16, 2.95]	2016			
Nassour-2017	40	193	44	235	20.9%	1.13 [0.70, 1.83]	2017			
Zimmerman-2017	46	211	53	280	23.6%	1.19 [0.77, 1.86]	2017			
Goh-2018	0	10	3	20	1.5%	0.24 [0.01, 5.08]	2018	•	_	
Xourafas-2018	74	409	81	418	43.5%	0.92 [0.65, 1.30]	2018			
Zhang-2018	3	20	5	20	2.8%	0.53 [0.11, 2.60]	2018	-		
Oosten-2020	4	90	5	90	3.2%	0.79 [0.21, 3.05]	2020	. —	•	
Xu-2021	1	24	3	37	1.5%	0.49 [0.05, 5.04]	2021	•		
Total (95% CI)		984		1125	100.0%	0.99 [0.79, 1.24]			•	
Total events	172		199							
Heterogeneity: Chi ² =	3.28, df =	7 (P=	0.86); I ² =	:0%						
Test for overall effect	-							11 11 /		
restion overall effect.	Z = 0.08	(P = 0.9	14)					0.1 0.2	PPD IPD	10
	Z = 0.08	(P = 0.9	14)					0.1 0.2	RPD LPD	10
B DGE	2 = 0.08	(P = 0.9	14)					0.1 0.2	RPD LPD	10
B DGE	Z = 0.08	(P = 0.9	14) I PD	1		Odds Batio		0.1 0.2	RPD LPD	10
B DGE Study or Subgroup	Z = 0.08 RPD Events	(P = 0.9) Total	LPD Events	Total	Weight	Odds Ratio M.H. Fixed, 95% Cl	Year	0.1 0.2	Codds Ratio	10
B DGE <u>Study or Subgroup</u>	Z = 0.08 RPE Events	(P = 0.9) <u>Total</u> 27	LPD Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI 0.59 (0.09.3.84)	Year 2016		Odds Ratio	10
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017	2 = 0.08 RPE <u>Events</u> 2 33	(P = 0.9) <u>Total</u> 27 211	LPD <u>Events</u> 3 49	Total 25 280	Weight 2.0% 25.1%	Odds Ratio M-H, Fixed, 95% CI 0.59 (0.09, 3.84) 0.87 (0.54, 1, 42)	<u>Year</u> 2016 2017		Odds Ratio M.H. Fixed, 95% Cl	
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2017	2 = 0.08 RPE <u>Events</u> 2 33 28	(P = 0.9) <u>Total</u> 27 211 193	4) LPD <u>Events</u> 3 49 43	Total 25 280 235	Weight 2.0% 25.1% 23.4%	Odds Ratio <u>M-H, Fixed, 95% C1</u> 0.59 (0.09, 3.84) 0.87 (0.54, 1.42) 0.76 fu d5 1 271	Year 2016 2017 2017		Odds Ratio	10
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2018	2 = 0.08 RPE <u>Events</u> 2 33 28 2	(P = 0.9 Total 27 211 193 20	LPD <u>Events</u> 3 49 43 1	Total 25 280 235 20	Weight 2.0% 25.1% 23.4% 0.6%	Odds Ratio <u>M-H, Fixed, 95% C1</u> 0.59 (0.09, 3.84) 0.87 (0.54, 1.42) 0.76 (0.45, 1.27) 2.11 (0.18, 25 35)	Year 2016 2017 2017 2018		Odds Ratio	10
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2017 Zhang-2018 Xourafas-2018	2 = 0.08 RPE <u>Events</u> 2 33 28 2 66	(P = 0.9) <u>Total</u> 27 211 193 20 409	LPD <u>Events</u> 3 49 43 1 71	Total 25 280 235 20 418	Weight 2.0% 25.1% 23.4% 0.6% 41.5%	Odds Ratio M-H, Fixed, 95% CI 0.59 [0.09, 3.84] 0.87 [0.54, 1.42] 0.76 [0.45, 1.27] 2.11 [0.18, 25.35] 0.94 [0.65, 1.38]	Year 2016 2017 2017 2018 2018		Odds Ratio M-H, Fixed, 95% Cl	10
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2017 Zhang-2018 Xourafas-2018 Onsten-2020	2 = 0.08 RPE <u>Events</u> 2 33 28 2 66 7	(P = 0.9 Total 27 211 193 20 409 90	LPD <u>Events</u> 3 49 43 1 71 10	Total 25 280 235 20 418 90	Weight 2.0% 25.1% 23.4% 0.6% 41.5% 6.5%	Odds Ratio M-H, Fixed, 95% C1 0.59 [0.09, 3.84] 0.87 [0.54, 1.42] 0.76 [0.45, 1.27] 2.11 [0.18, 25.35] 0.94 [0.65, 1.36] 0.67 [0.24 1.86]	Year 2016 2017 2017 2018 2018 2018		Odds Ratio M.H. Fixed, 95% Cl	10
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2017 Zhang-2018 Xourafas-2018 Oosten-2020 Xiu-2021	Z = 0.08 RPE <u>Events</u> 2 33 28 2 66 7 0	(P = 0.9 Total 27 211 193 20 409 90 24	LPD <u>Events</u> 3 49 43 1 71 10 10	Total 25 280 235 20 418 90 37	Weight 2.0% 25.1% 23.4% 0.6% 41.5% 6.5% 0.8%	Odds Ratio <u>M-H, Fixed, 95% CI</u> 0.59 [0.09, 3.84] 0.76 [0.45, 1.27] 2.11 [0.18, 25.35] 0.94 [0.65, 1.36] 0.67 [0.24, 1.86] 0.57 [0.02, 12, 70]	Year 2016 2017 2017 2018 2018 2020 2021		Odds Ratio M-H, Fixed, 95% Cl	
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2017 Zhang-2018 Xourafas-2018 Oosten-2020 Xu-2021	Events 2 33 28 66 7 0	(P = 0.9 Total 27 211 193 20 409 90 24	LPD <u>Events</u> 3 49 43 1 71 10 10	Total 25 280 235 20 418 90 37	Weight 2.0% 25.1% 23.4% 0.6% 41.5% 6.5% 0.8%	Odds Ratio <u>M-H, Fixed, 95% CI</u> 0.59 [0.09, 3.84] 0.87 [0.54, 1.42] 0.76 [0.45, 1.27] 2.11 [0.18, 25.35] 0.94 [0.65, 1.36] 0.67 [0.24, 1.86] 0.50 [0.02, 12.70]	Year 2016 2017 2017 2018 2018 2020 2021		Odds Ratio M-H, Fixed, 95% Cl	
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2017 Zhang-2018 Xourafas-2018 Oosten-2020 Xu-2021 Total (95% CI)	2 = 0.08 f <u>Events</u> 2 33 28 2 66 7 0	(P = 0.9 Total 27 211 193 20 409 90 24 974	LPD <u>Events</u> 3 49 43 1 71 10 1	Total 25 280 235 20 418 90 37 1105	Weight 2.0% 25.1% 23.4% 0.6% 41.5% 6.5% 0.8% 100.0%	Odds Ratio M-H, Fixed, 95% CI 0.59 [0.09, 3.84] 0.87 [0.54, 1.42] 0.76 [0.45, 1.27] 2.11 [0.18, 25.35] 0.94 [0.65, 1.36] 0.67 [0.24, 1.86] 0.50 [0.02, 12.70] 0.86 [0.68, 1.10]	Year 2016 2017 2017 2018 2018 2020 2021		Odds Ratio Odds Ratio M-H, Fixed, 95% Cl	
B DGE <u>Study or Subgroup</u> Liu-2016 Zimmerman-2017 Nassour-2017 Zhang-2018 Xourafas-2018 Oosten-2020 Xu-2021 Total (95% CI) Total events	Z = 0.08 f <u>Events</u> 2 33 28 2 66 7 0 138	(P = 0.9 Total 27 211 193 20 409 90 24 974	44) Events 3 49 43 1 71 10 1 1 178	Total 25 280 235 20 418 90 37 1105	Weight 2.0% 25.1% 23.4% 0.8% 41.5% 6.5% 0.8% 100.0%	Odds Ratio M-H, Fixed, 95% C1 0.59 [0.09, 3.84] 0.76 [0.45, 1.27] 2.11 [0.18, 25.35] 0.94 [0.65, 1.36] 0.67 [0.24, 1.86] 0.50 [0.02, 12.70] 0.86 [0.68, 1.10]	Year 2016 2017 2017 2018 2018 2020 2021		Odds Ratio Odds Ratio M-H, Fixed, 95% Cl	

FIGURE 5 | Forest plot of comparison of RPD versus LPD. (A) Forest plot for postoperative pancreatic fistula. (B) Forest plot for delayed gastric emptying. RPD, robotic pancreaticoduodenectomy; LPD, laparoscopic pancreaticoduodenectomy.



LPD group (OR = 0.63; 95% CI 0.33 to 1.21; p = 0.16) (**Figure 6B**).

Conversion Rate

Seven studies with a total of 3,512 patients reported a conversion rate. The meta-analysis revealed that RPD presented lower conversion rate

Reoperation

Reoperation data were available in 7 studies. The meta-analysis indicated no significant difference in reoperation between the

than the LPD group (OR = 0.45; 95% CI 0.36 to 0.56; p < 0.00001),

with no heterogeneity $(I^2 = 0\%)$ in the FEM (**Figure 7A**).

RPD and LPD groups (OR = 0.83; 95% CI 0.59 to 1.18; p = 0.31), with no heterogeneity (I² = 0%) in the FEM (**Figure 7B**).

Publication Bias

The publication bias was investigated by Begg's funnel plot. All studies lie inside the 95% CIs in the funnel plot of overall complications and POPF, which indicated no obvious potential publication bias (**Figure 8**).

DISCUSSION

Minimally invasive surgery has become a worldwide trend to reduce wounds and mitigate pain. However, the role of RPD has not been well established in the era of minimally invasive surgery. Since Giulianotti et al. first performed RPD surgery in 2003 (3), with the development of robotic equipment and the accumulation of surgical experience, RPD has been gradually implemented in the field of pancreatic surgery (21). During the past decade, substantial changes have been introduced in the management of pancreatic cancer with an increased enthusiasm for minimally invasive approaches. Over the recent years, more and more studies have explored the safety and efficiency of RPD. Several studies have indicated that RPD is safe and feasible, and the curative effect is similar to that of the open approach, but it requires a higher requirement for the operator and is relatively time-consuming (5, 22). The introduction of a robotic surgical platform came with several advantages over the laparoscopic approach, yielding a better range of motion, improved ergonomics, and enhanced dexterity while allowing 3D optics.

Although robotic surgery is considered to be superior to laparoscopy in several disciplines, including colorectal, gastric, pancreatic, gynecological, and urological procedures, there are some controversies about the safety and efficacy of RPD compared with LPD (23–27). In order to explore the real efficacy of RPD, this meta-analysis included relevant studies from 2016 to 2021 to explore the safety and effectiveness of RPD and LPD. All of the included studies were retrospective studies, and all of them were of relatively high quality according to NOS, as shown in **Table 1**.

Three was only one meta-analysis comparing perioperative and oncologic outcomes of RPD to LPD published (8). However, the sample size of this meta-analysis was relatively small. The study of Kamarajah et al. only focused on perioperative outcomes between RPD and LPD, and 6 articles with 3,462 patients were included. They found that RPD has similar morbidity, blood loss, operative time, shorter length of stay, lower conversion rates, and blood transfusion rates in comparison with LPD (8).

Operating time is one of the most considered surgical variables when robotic surgery is compared with laparoscopy. This metaanalysis revealed that RPD has a similar operative time compared with laparoscopy, in spite of the robotic system needing much time to set and dock. The meta-analysis showed that RPD was associated with less blood loss, which was contrary to the study of Kamarajah et al. (8). It could be explained that the robotic platform provides a magnified 3D image and eliminates hand tremor, allowing for precise suturing, better control of small blood vessel bleeding, and reduction of blood loss (13). Another reason is that patients in the RPD group are highly selected and the tumor is of early stage and/or begin. This is why RPD has less vascular resection and blood loss.

Α Conversion rate RPD LPD Odds Ratio Odds Ratio Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl Study or Subgroup Events Total Events Total Year 0.30 [0.01, 7.63] 2016 1 iu-2016 n 27 25 0.6% 1 Nassour-2017 22 193 18.9% 0.37 [0.22, 0.62] 61 235 2017 Zimmerman-2017 23.1% 24 211 280 0.33 (0.20, 0.55) 2017 78 28 0.54 [0.35, 0.82] Nassour-2018 165 402 1458 26.4% 2018 Goh-2018 ۵ 20 1.1% 0.17 [0.01, 3.59] 2018 10 4 --Xourafas-2018 50 409 86 418 29.0% 0.54 [0.37, 0.79] 2018 Xu-2021 0.49 [0.05, 5.04] 2021 24 3 37 0.9% Total (95% CI) 100.0% 0.45 [0.36, 0.56] 1039 2473 Total events 125 635 Heterogeneity: Chi² = 3.94, df = 6 (P = 0.68); l² = 0% 0.01 0.1 10 100 Test for overall effect: 7 = 7.05 (P < 0.00001) RPD LPD в Reoperation RPD LPD Odds Ratio Odds Ratio M-H, Fixed, 95% Cl Study or Subgroup ents Total ents Total Weight Year M-H. Fixed. 95% Cl 1 iu-2016 n 27 25 2.2% 0.30 [0.01, 7.63] 2016 1 Zimmerman-2017 211 22 280 25.5% 14 0.83 [0.42, 1.67] 2017 21.9% 0.87 [0.42, 1.83] Nassour-2017 13 193 18 235 2017 41.7% Xourafas-2018 31 418 0.78 [0.45, 1.35] 2018 24 409 Goh-2018 0 10 2 20 2.4% 0.35 [0.02, 8.06] 2018 3 Zhang-2018 3 20 20 3.7% 1.00 (0.18, 5.67) 2018 4 90 2 90 2.8% Oosten-2020 2.05 [0.37, 11.47] 2020 Total (95% CI) 1088 100.0% 0.83 [0.59, 1.18] 960 Total events 58 79 Heterogeneity: Chi² = 1.84, df = 6 (P = 0.93); l² = 0% 0.01 0.1 10 100 Test for overall effect: Z = 1.01 (P = 0.31) RPD IPD FIGURE 7 | Forest plot of comparison of RPD versus LPD. (A) Forest plot for conversion rate. (B) Forest plot for reoperation. RPD, robotic pancreaticoduodenectomy;

LPD, laparoscopic pancreaticoduodenectomy.



With regard to the complications, our study demonstrated no significant difference between the RPD and LPD techniques overall and regarding major complications. There is no significant difference in terms of POPF and DGE, reoperation, and blood transfusion. POPF and DGE are two main and serious technical complications and play a vital role in postoperative recovery. Our meta-analysis revealed no significant difference between the RPD and LPD. In regard to vascular resection, our study showed that RPD has evidently lower vascular resection rates than laparoscopy. The main reason is that patients for RPD are highly selected and hardly with tumor involvement of the portal vein or superior mesenteric vein. In addition, when looking at more frequent combined vascular resections in LPD, RPD is believed to be applied in well-selected and less complicated patients, leading to favorable short-term postoperative surgical outcomes. Regarding the number of LN dissections, this meta-analysis showed that RPD had more harvested LNs than LPD. It could be explained that RPD has a magnified 3D view and a tremor filter, which contribute to precise dissection and lymphadenectomy. What is more, some studies included pylorus-preserving pancreaticoduodenectomy and standard pancreaticoduodenectomy, which may determine the number of retrieved LNs due to additional LNs from omentum or peri-gastric LNs. In addition, the detail for each group that has a particular surgical approach is not reported and may represent some selection bias.

When it comes to long-term survival, to the best of our knowledge, there is still no RCT comparing the long-term survival between RPD and LPD. The largest overall survival outcome data of RPD and LPD come from the USA (17). Nassour et al. utilized the U.S. National Cancer Database, which reported 1,623 minimally invasive pancreaticoduodenectomy (165 underwent RPD and 1,425 underwent LPD) and revealed no difference in median overall survival for pancreatic adenocarcinoma between RPD and LPD (RPD 22.7 months vs. LPD 20.7 months; p = 0.445). RPD has similar 3-year overall survival rates with LPD (33% vs. 31%, p = 0.205) (17).

Although the present meta-analysis included 9 studies to draw a more convincing conclusion, there are some limitations in this study that need to be addressed. Firstly, we acknowledge that this meta-analysis does have some limitations related to possible publication bias because of the exclusion of non-English and non-Chinese articles, and patients' demographic and comorbidity heterogeneities are high in some included studies. Detailed oncologic data such as staging of pancreatic tumor, histologic subtype, type of surgery, and tumor type are lacking in some studies. Given that these clinical factors may considerably impact outcomes and overall survival, the absence of these components should be considered as an additional limitation and a possible confounder. Secondly, only one study reported longterm survival; further, high-quality RCTs with survival outcomes are expected to assess the safety and efficiency of RPD. Additionally, all studies in this review do not stratify outcomes between benign and malignant indications, which could cause a potential source of bias and have an effect on reliable conclusions. Chronologically, RPD is the next surgical approach to LPD, which means that surgical technique and concept might be basically derived from direct and indirect experiences of LPD. Techniques for RPD might be positively modified from those of LPD. What is more, high heterogeneity among studies exists; therefore, results from metaanalysis should be taken with caution.

In conclusion, the present meta-analysis comparing RPD and LPD revealed that RPD is a safe and feasible approach. Further,

REFERENCES

- Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the Outcomes of Pancreatic Cancer Surgery. Nat Rev Clin Oncol (2019) 16(1):11–26. doi: 10.1038/s41571-018-0112-1
- Gagner M, Pomp A. Laparoscopic Pylorus-Preserving Pancreatoduodenectomy. Surg Endosc (1994) 8(5):408–10. doi: 10.1007/BF00642443
- Giulianotti PC, Coratti A, Angelini M, Sbrana F, Cecconi S, Balestracci T, et al. Robotics in General Surgery: Personal Experience in a Large Community Hospital. Arch Surg (2003) 138(7):777–84. doi: 10.1001/archsurg.138.7.777
- Gumbs AA, Rodriguez Rivera AM, Milone L, Hoffman JP. Laparoscopic Pancreatoduodenectomy: A Review of 285 Published Cases. Ann Surg Oncol (2011) 18(5):1335–41. doi: 10.1245/s10434-010-1503-4
- Buchs NC, Addeo P, Bianco FM, Ayloo S, Benedetti E, Giulianotti PC. Robotic Versus Open Pancreaticoduodenectomy: A Comparative Study at a Single Institution. World J Surg (2011) 35(12):2739–46. doi: 10.1007/s00268-011-1276-3
- Baker EH, Ross SW, Seshadri R, Swan RZ, Iannitti DA, Vrochides D, et al. Robotic Pancreaticoduodenectomy: Comparison of Complications and Cost to the Open Approach. *Int J Med Robot* (2016) 12(3):554–60. doi: 10.1002/rcs.1688
- Zureikat AH, Postlewait LM, Liu Y, Gillespie TW, Weber SM, Abbott DE, et al. A Multi-Institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. *Ann Surg* (2016) 264(4):640–9. doi: 10.1097/SLA.00000000001869
- Kamarajah SK, Bundred J, Marc OS, Jiao LR, Manas D, Abu Hilal M, et al. Robotic Versus Conventional Laparoscopic Pancreaticoduodenectomy a Systematic Review and Meta-Analysis. *Eur J Surg Oncol* (2020) 46(1):6–14. doi: 10.1016/j.ejso.2019.08.007
- Moher D, Liberati A, Tetzlaff J, Altman DGPRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *BMJ* (2009) 339:b2535. doi: 10.1136/bmj.b2535
- Lo CK. Crded Laparoscopic Pancreaticoduodenectomy Versus Laparoscopic Pancreaticoduodenectomy for Periampullary Neoplasms: A Comparative Study of a Single Center. Surg Endosc (2017) 31(6):2380–6. doi: 10.1007/ s00464-016-5238-6
- Hozo SP, Djulbegovic B, Hozo I. Estimating the Mean and Variance from the Median, Range, and the Size of a Sample. *BMC Med Res Methodol* (2005) 5:13. doi: 10.1186/1471-2288-5-13

large-scale and multicenter clinical RCTs are expected to assess the efficiency of RPD.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Study concept and design: LO, JZ, QF, and ZZ. Acquisition of data: all authors. Analysis and interpretation of data: LO, JZ, QF, ZZ, and HM. Drafting of the manuscript: LO, JZ, QF, ZZ, and GZ). Critical revision of the manuscript for important intellectual content: GZ. Administrative, technical, or material support, and study supervision: GZ. All authors contributed to the article and approved the submitted version.

- Liu R, Zhang T, Zhao ZM, Tan XL, Zhao GD, Zhang X, et al. The Surgical Outcomes of Robot-Assisted Laparoscopic Pancreaticoduodenectomy versus Laparoscopic Pancreaticoduodenectomy for Periampullary Neoplasms: A Comparative Study of a Single Center. Surg Endosc (2017) 31(6):2380–6. doi: 10.1007/s00464-016-5238-6
- Nassour I, Wang SC, Porembka MR, Yopp AC, Choti MA, Augustine MM, et al. Robotic Versus Laparoscopic Pancreaticoduodenectomy: A NSQIP Analysis. J Gastrointest Surg (2017) 21(11):1784–92. doi: 10.1007/s11605-017-3543-6
- Zimmerman AM, Roye DG, Charpentier KP. A Comparison of Outcomes Between Open, Laparoscopic and Robotic Pancreaticoduodenectomy. *HPB* (Ox) (2018) 20(4):364–9. doi: 10.1016/j.hpb.2017.10.008
- Goh BKP, Low TY, Kam JH, Lee SY, Chan CY. Initial Experience With Laparoscopic and Robotic Surgery for the Treatment of Periampullary Tumours: Single Institution Experience With the First 30 Consecutive Cases. ANZ J Surg (2019) 89(4):E137–41. doi: 10.1111/ans.15033
- Zhang Y, Hong D, Zhang C, Hu Z. Total Laparoscopic Versus Robot-Assisted Laparoscopic Pancreaticoduodenectomy. *Biosci Trends* (2018) 12(5):484–90. doi: 10.5582/bst.2018.01236
- Nassour I, Choti MA, Porembka MR, Yopp AC, Wang SC, Polanco PM. Robotic-Assisted Versus Laparoscopic Pancreaticoduodenectomy: Oncological Outcomes. *Surg Endosc* (2018) 32(6):2907–13. doi: 10.1007/ s00464-017-6002-2
- Xourafas D, Pawlik TM, Cloyd JM. Independent Predictors of Increased Operative Time and Hospital Length of Stay Are Consistent Across Different Surgical Approaches to Pancreatoduodenectomy. J Gastrointest Surg (2018) 22(11):1911–9. doi: 10.1007/s11605-018-3834-6
- van Oosten AF, Ding D, Habib JR, Irfan A, Schmocker RK, Sereni E, et al. Perioperative Outcomes of Robotic Pancreaticoduodenectomy: A Propensity-Matched Analysis to Open and Laparoscopic Pancreaticoduodenectomy. *J Gastrointest Surg* (2021) 25(7):1795–804. doi: 10.1007/s11605-020-04869-z
- GP TU, JC SUN, NIE WP. Comparison of Efficacy and Safety of Robotic-Assisted Versus Laparoscopic Pancreaticoduodenectomy for Pancreatic Cancer. Chin J Gen Surg (2020) 3):268–75. doi: :10.7659/j.issn.1005-6947.2020.03.003
- Stafford AT, Walsh RM. Robotic Surgery of the Pancreas: The Current State of the Art. J Surg Oncol (2015) 112(3):289–94. doi: 10.1002/jso.23952

- Yan Q, Xu LB, Ren ZF, Liu C. Robotic Versus Open Pancreaticoduodenectomy: A Meta-Analysis of Short-Term Outcomes. Surg Endosc (2020) 34(2):501–9. doi: 10.1007/s00464-019-07084-3
- Kim CW, Kim CH, Baik SH. Outcomes of Robotic-Assisted Colorectal Surgery Compared With Laparoscopic and Open Surgery: A Systematic Review. J Gastrointest Surg (2014) 18(4):816–30. doi: 10.1007/s11605-014-2469-5
- 24. Feng Q, Ma H, Qiu J, Du Y, Zhang G, Li P, et al. Comparison of Long-Term and Perioperative Outcomes of Robotic Versus Conventional Laparoscopic Gastrectomy for Gastric Cancer: A Systematic Review and Meta-Analysis of PSM and RCT Studies. *Front Oncol* (2021) 11:759509. doi: 10.3389/fonc.2021.759509
- Leow JJ, Heah NH, Chang SL, Chong YL, Png KS. Outcomes of Robotic Versus Laparoscopic Partial Nephrectomy: An Updated Meta-Analysis of 4,919 Patients. J Urol (2016) 196(5):1371–7. doi: 10.1016/j.juro.2016.06.011
- 26. Feng Q, Jiang C, Feng X, Du Y, Liao W, Jin H, et al. Robotic Versus Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. *Front Oncol* (2021) 11:752236. doi: 10.3389/fonc.2021.752236
- 27. Xie W, Cao D, Yang J, Shen K, Zhao L. Robot-Assisted Surgery Versus Conventional Laparoscopic Surgery for Endometrial Cancer: A Systematic

Review and Meta-Analysis. J Cancer Res Clin Oncol (2016) 142(10):2173–83. doi: 10.1007/s00432-016-2180-x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ouyang, Zhang, Feng, Zhang, Ma and Zhang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.